The European Survey on Anaemia Management (ESAM): Indicators of current practices of anaemia care in patients with end-stage renal disease

I. C. Macdougall, W. H. Hörl, C. Jacobs, F. Valderrábano, I. Parrondo, Ivo L Abraham, A. E. Peterson

Research output: Contribution to journalArticle

Abstract

There is persistent variability in the practice patterns of anaemia management in patients with end-stage renal disease. In an effort to document existing practice patterns before the introduction of the European Best Practice Guidelines (EBPG), the European Survey on Anaemia Management (ESAM) was launched in 14 Western European countries. Data were collected longitudinally for 6 months. Findings are reported on 14 527 patients, of which 13 121 (90.3%) were receiving haemodialysis and 1406 (9.7%) were receiving peritoneal dialysis. The ESAM found that epoetin treatment is most often initiated after dialysis has begun, with haemoglobin (Hb) levels (mean = 8.7 g/dl) lower than the EBPG recommendation. For target Hb, the vast majority of patients were allocated values at or exceeding the EBPG recommended level, yet in only 53.6% of patients were these targets reached at 6 months. During any given month of the survey, between 15% and 22% of haemodialysis patients and between 41% and 45% of peritoneal dialysis patients had absolute iron deficiency; however, almost 19% of haemodialysis patients and 34% of peritoneal dialysis patients received no iron supplementation during the 6-month study. The ESAM documents the significant shortfall between EBPG recommendations and de facto clinical management of anaemia in end-stage renal disease. Patients are being treated with epoetin too late in the course of their anaemia, iron supplementation is underused and target Hb levels are not being achieved.

Original languageEnglish (US)
Pages (from-to)3-14
Number of pages12
JournalErythropoiesis: New Dimensions in the Treatment of Anaemia
Volume11
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Chronic Kidney Failure
Practice Guidelines
Anemia
Patient Care
Peritoneal Dialysis
Renal Dialysis
Hemoglobins
Iron
Surveys and Questionnaires
Dialysis

ASJC Scopus subject areas

  • Hematology

Cite this

The European Survey on Anaemia Management (ESAM) : Indicators of current practices of anaemia care in patients with end-stage renal disease. / Macdougall, I. C.; Hörl, W. H.; Jacobs, C.; Valderrábano, F.; Parrondo, I.; Abraham, Ivo L; Peterson, A. E.

In: Erythropoiesis: New Dimensions in the Treatment of Anaemia, Vol. 11, No. 1, 2001, p. 3-14.

Research output: Contribution to journalArticle

@article{b1895f1be41649d288083c9485e83902,
title = "The European Survey on Anaemia Management (ESAM): Indicators of current practices of anaemia care in patients with end-stage renal disease",
abstract = "There is persistent variability in the practice patterns of anaemia management in patients with end-stage renal disease. In an effort to document existing practice patterns before the introduction of the European Best Practice Guidelines (EBPG), the European Survey on Anaemia Management (ESAM) was launched in 14 Western European countries. Data were collected longitudinally for 6 months. Findings are reported on 14 527 patients, of which 13 121 (90.3{\%}) were receiving haemodialysis and 1406 (9.7{\%}) were receiving peritoneal dialysis. The ESAM found that epoetin treatment is most often initiated after dialysis has begun, with haemoglobin (Hb) levels (mean = 8.7 g/dl) lower than the EBPG recommendation. For target Hb, the vast majority of patients were allocated values at or exceeding the EBPG recommended level, yet in only 53.6{\%} of patients were these targets reached at 6 months. During any given month of the survey, between 15{\%} and 22{\%} of haemodialysis patients and between 41{\%} and 45{\%} of peritoneal dialysis patients had absolute iron deficiency; however, almost 19{\%} of haemodialysis patients and 34{\%} of peritoneal dialysis patients received no iron supplementation during the 6-month study. The ESAM documents the significant shortfall between EBPG recommendations and de facto clinical management of anaemia in end-stage renal disease. Patients are being treated with epoetin too late in the course of their anaemia, iron supplementation is underused and target Hb levels are not being achieved.",
author = "Macdougall, {I. C.} and H{\"o}rl, {W. H.} and C. Jacobs and F. Valderr{\'a}bano and I. Parrondo and Abraham, {Ivo L} and Peterson, {A. E.}",
year = "2001",
language = "English (US)",
volume = "11",
pages = "3--14",
journal = "Erythropoiesis: New Dimensions in the Treatment of Anaemia",
issn = "0956-6309",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - The European Survey on Anaemia Management (ESAM)

T2 - Indicators of current practices of anaemia care in patients with end-stage renal disease

AU - Macdougall, I. C.

AU - Hörl, W. H.

AU - Jacobs, C.

AU - Valderrábano, F.

AU - Parrondo, I.

AU - Abraham, Ivo L

AU - Peterson, A. E.

PY - 2001

Y1 - 2001

N2 - There is persistent variability in the practice patterns of anaemia management in patients with end-stage renal disease. In an effort to document existing practice patterns before the introduction of the European Best Practice Guidelines (EBPG), the European Survey on Anaemia Management (ESAM) was launched in 14 Western European countries. Data were collected longitudinally for 6 months. Findings are reported on 14 527 patients, of which 13 121 (90.3%) were receiving haemodialysis and 1406 (9.7%) were receiving peritoneal dialysis. The ESAM found that epoetin treatment is most often initiated after dialysis has begun, with haemoglobin (Hb) levels (mean = 8.7 g/dl) lower than the EBPG recommendation. For target Hb, the vast majority of patients were allocated values at or exceeding the EBPG recommended level, yet in only 53.6% of patients were these targets reached at 6 months. During any given month of the survey, between 15% and 22% of haemodialysis patients and between 41% and 45% of peritoneal dialysis patients had absolute iron deficiency; however, almost 19% of haemodialysis patients and 34% of peritoneal dialysis patients received no iron supplementation during the 6-month study. The ESAM documents the significant shortfall between EBPG recommendations and de facto clinical management of anaemia in end-stage renal disease. Patients are being treated with epoetin too late in the course of their anaemia, iron supplementation is underused and target Hb levels are not being achieved.

AB - There is persistent variability in the practice patterns of anaemia management in patients with end-stage renal disease. In an effort to document existing practice patterns before the introduction of the European Best Practice Guidelines (EBPG), the European Survey on Anaemia Management (ESAM) was launched in 14 Western European countries. Data were collected longitudinally for 6 months. Findings are reported on 14 527 patients, of which 13 121 (90.3%) were receiving haemodialysis and 1406 (9.7%) were receiving peritoneal dialysis. The ESAM found that epoetin treatment is most often initiated after dialysis has begun, with haemoglobin (Hb) levels (mean = 8.7 g/dl) lower than the EBPG recommendation. For target Hb, the vast majority of patients were allocated values at or exceeding the EBPG recommended level, yet in only 53.6% of patients were these targets reached at 6 months. During any given month of the survey, between 15% and 22% of haemodialysis patients and between 41% and 45% of peritoneal dialysis patients had absolute iron deficiency; however, almost 19% of haemodialysis patients and 34% of peritoneal dialysis patients received no iron supplementation during the 6-month study. The ESAM documents the significant shortfall between EBPG recommendations and de facto clinical management of anaemia in end-stage renal disease. Patients are being treated with epoetin too late in the course of their anaemia, iron supplementation is underused and target Hb levels are not being achieved.

UR - http://www.scopus.com/inward/record.url?scp=0035174946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035174946&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035174946

VL - 11

SP - 3

EP - 14

JO - Erythropoiesis: New Dimensions in the Treatment of Anaemia

JF - Erythropoiesis: New Dimensions in the Treatment of Anaemia

SN - 0956-6309

IS - 1

ER -